Health Care • Biotechnology: Pharmaceutical Preparations
$29.21 ▼ -0.78
(-2.60%)
MKT CAP: $2.17B • VOL: 931.3K
52W L $10 52W H $34
XNCR // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $125.6M | $110.5M | $174.6M |
| YoY Revenue Growth % | +13.7% | -36.7% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$177.5M | -$178.4M | -$132.4M |
| Operating Margin % | -80.0% | -80.0% | -75.8% |
| Net Income (GAAP) | -$91.9M | -$232.6M | -$133.1M |
| EBITDA (Normalized) | -$175.0M | -$173.5M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$135.1M | -$202.2M | -$77.9M |
| Capital Expenditures (CapEx) | $3.1M | $6.1M | — |
| Free Cash Flow (FCF) | -$138.3M | -$208.3M | -$77.9M |
| FCF Margin % | -80.0% | -80.0% | -44.6% |
| Return on Invested Capital (ROIC %) | -21.3% | -18.7% | — |
| Cash & Short-Term Equivalents | $54.1M | $40.9M | — |
| Total Debt (Short + Long Term) | $76.5M | $115.2M | — |
| Total Stockholders' Equity | $635.6M | $677.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR XNCR.